Resultados en la práctica asistencial y coste marginal del tratamiento con tocilizumab en pacientes COVID-19

OBJECTIVE: To describe the marginal cost and survival of patients treated with tocilizumab in a university hospital under real-life conditions and to evaluate factors that could influence costs and health outcomes will be evaluated. METHODS: Observational, single-center, retrospective study of a coh...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Molina, Antonio, Alós-Almiñana, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U. 2023
Materias:
Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750892/
https://www.ncbi.nlm.nih.gov/pubmed/36635189
http://dx.doi.org/10.1016/j.farma.2022.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750892/
https://www.ncbi.nlm.nih.gov/pubmed/36635189
http://dx.doi.org/10.1016/j.farma.2022.12.003

Ejemplares similares